← Eichor
Study identifier: NCT04224064 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas

Condition: Liposarcoma · Atypical Lipomatous Tumor  ·  Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle

PhaseNA
Planned participants158
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.

This description comes directly from the study's public registry record.

Talk to the study team

Jean-Pierre BLEUSE, MD  ·  0467613102  ·  DRCI-icm105@icm.unicancer.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Institut du Cancer de Montpellier - Val d'AurelleMontpellier, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04224064